Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • Shenqi Fuzheng and SRC/PI3K/AKT in Glioma

    2026-10-08

    Shenqi Fuzheng and SRC/PI3K/AKT in Glioma

    Glioma remains a difficult research target because invasive growth, rapid proliferation, treatment resistance, and biological heterogeneity limit the effectiveness of available interventions. The 2024 Journal of Ethnopharmacology paper, Network pharmacology-based investigation of the effects of Shenqi Fuzheng injection on glioma proliferation and migration via the SRC/PI3K/AKT signaling pathway, addresses this challenge by combining systems-level target analysis with experimental validation.

    Rather than treating Shenqi Fuzheng injection (SFI) as a single-target drug, the study examines it as a multicomponent formulation. Its central proposal is that interactions among SFI-associated targets converge on SRC/PI3K/AKT signaling, a pathway with established roles in cell survival, proliferation, migration, and tumor progression. The paper is therefore most useful as a mechanistic framework and evidence-generating study, not as clinical proof of an anti-glioma treatment.

    Study Background and Research Question

    SFI contains material derived primarily from Codonopsis pilosula and Astragalus membranaceus. It is used clinically as an adjunct during cancer chemotherapy in some settings, but the molecular basis for any activity against glioma cells has remained insufficiently defined. The authors therefore asked two connected questions: which SFI-associated targets overlap with glioma-related biology, and can the resulting pathway predictions be supported by cellular and animal observations?

    This question is important because botanical formulations can influence multiple biological processes at once. A conventional single-target interpretation may overlook interactions between intracellular signaling, cell-cycle regulation, epithelial-to-mesenchymal transition (EMT)-associated behavior, and the tumor microenvironment. The study instead places SFI within a network pharmacology model and then tests whether the predicted biology is consistent with measurable changes in glioma models.

    Key Innovation from the Reference Study

    The main innovation is the integration of computational target mapping with several layers of biological validation. According to the reference paper, the authors identified 26 major active components associated with SFI and 110 SFI-related targets. They compared these with 3,343 glioma-related targets and reported 79 shared targets. Enrichment analysis then highlighted SRC/PI3K/AKT signaling as a candidate pathway connecting SFI-associated molecular activity with glioma proliferation and migration.

    This design is more informative than presenting a list of phytochemicals or isolated pathway markers alone. It creates a traceable logic chain: formulation components are linked to predicted targets, shared targets are connected to disease-relevant pathways, and pathway-level predictions are compared with cell and tumor-model findings. The published study consequently provides a candidate mechanism that can be examined in more focused work.

    However, the computational layer should be interpreted as hypothesis generation. Target overlap and enrichment do not demonstrate that every predicted component reaches glioma tissue, binds the proposed target, or contributes equally to the observed phenotype. The innovation is therefore methodological integration rather than definitive proof that one pathway fully explains the activity of SFI.

    Conceptual Study Design and Evidence Scope

    Network pharmacology layer

    The computational analysis assembled information about SFI components, predicted or reported molecular targets, and glioma-associated genes. The intersection of these datasets was used to prioritize candidate targets and signaling pathways. SRC, PI3K, and AKT emerged as a mechanistic axis of interest because the pathway is biologically compatible with control of proliferation, survival, migration, and cell-state transitions.

    This approach provides breadth across a complex formulation. It also helps prioritize experimental questions, such as whether pathway-associated proteins change alongside functional readouts and whether the biological effects appear in more than one glioma model. Its evidentiary value depends on the quality of the databases, target annotations, component selection, and assumptions used to define active ingredients.

    Cellular and animal validation layer

    The authors examined SFI-associated effects in U87 and T98G glioma cells, using complementary measures of cell growth, DNA synthesis, colony-forming capacity, migration, cell-cycle distribution, EMT-related marker expression, and pathway-associated proteins. The reported methods included CCK-8, EdU, colony-formation, scratch, Transwell, immunofluorescence, flow-cytometry, and Western-blot readouts. Taken together, these measurements address both phenotype and molecular association rather than relying on a single assay.

    For in vivo assessment, the study used GL261 cells in a transplanted mouse tumor model and evaluated tumor development with histological and immunohistochemical measures. This adds organism-level evidence to the cell-based findings, although the model remains a simplified representation of human glioma biology. Importantly, the study was designed to examine proliferation, migration, and signaling; it was not a direct test of a VEGF receptor inhibitor or a dedicated angiogenesis model.

    Core Findings and Why They Matter

    Reduced proliferation and altered cell-cycle behavior

    The paper reports that SFI inhibited proliferation in both U87 and T98G cells. EdU-associated proliferation measurements and other growth readouts were consistent with reduced cellular expansion. Flow-cytometry findings indicated S-phase blockage or arrest, suggesting that the reduction in growth was associated with altered cell-cycle progression rather than only nonspecific loss of cell viability.

    This distinction matters for interpretation. A treatment that changes cell-cycle distribution may affect tumor expansion even before a clear loss of cell number becomes evident. It also gives the SRC/PI3K/AKT hypothesis a functional context, because signaling through this axis can influence the balance between growth signals and cell-cycle control. Nevertheless, the reported data do not establish which SFI component is responsible for the cell-cycle effect.

    Suppressed migration and EMT-associated changes

    SFI also reduced migration-related behavior in the U87 and T98G models. The study associated this effect with downregulation of EMT markers. Because glioma cells are not epithelial tumors in the conventional sense, EMT terminology should be used cautiously; in this context, the markers are better viewed as indicators of a more migratory or mesenchymal-like cell state rather than as definitive proof of a complete epithelial-to-mesenchymal transition.

    The migration findings are significant because tumor expansion is not determined by proliferation alone. A compound or formulation that affects both cell-cycle progression and motility may influence multiple features of glioma aggressiveness. At the same time, in vitro migration assays do not reproduce the brain microenvironment, extracellular matrix complexity, vascular interactions, or infiltrative behavior of patient tumors.

    Evidence from the transplanted tumor model

    In the GL261 mouse model, the authors reported a marked reduction in tumor development after SFI-associated treatment, supported by histological and immunohistochemical evaluation. This result strengthens the biological plausibility of the cellular findings because it shows that the observed phenotype was not limited to an isolated cell culture context.

    Even so, the result should be described as preclinical evidence of antitumor activity in a transplanted model. It does not establish efficacy against human glioma, activity in infiltrative intracranial disease, or compatibility with standard clinical regimens. The study also does not show that tumor reduction was caused specifically by direct inhibition of glioma-cell SRC/PI3K/AKT signaling rather than by broader effects on the tumor environment.

    How the signaling interpretation should be framed

    The combined results support SRC/PI3K/AKT signaling as a candidate mechanism through which SFI may influence glioma growth and migration. They do not prove that this pathway is necessary for every reported effect. The strongest defensible conclusion is that network analysis, cellular phenotypes, pathway-associated protein changes, and animal observations point in the same direction. Causal pathway validation would require additional evidence that is not established by the supplied study summary.

    Comparison with Existing Internal Articles

    The internal article Shenqi Fuzheng, SRC/PI3K/AKT, and Glioma presents the same paper as a combined network-pharmacology and experimental study. Its value is primarily explanatory: it helps readers connect the predicted pathway with the reported effects on proliferation, migration, and tumor growth. The present interpretation adds emphasis on evidence hierarchy and the difference between pathway association and demonstrated causality.

    A second resource, Network Pharmacology Reveals SFI’s Anti-Glioma Mechanism via SRC/PI3K/AKT, focuses on the systems-biology framing of the article. That perspective is useful for researchers investigating multicomponent formulations, but it should be read alongside the original paper because database-derived target networks can overrepresent well-studied pathways. Neither internal article changes the primary limitation that SFI was not directly compared with a defined pathway-selective intervention in the reported work.

    Limitations and Transferability

    Several limitations shape how far these findings can be transferred. First, the formulation contains multiple constituents, and the study does not by itself identify which compounds are necessary, sufficient, or most biologically active. The reported 26-component network is a prioritization framework, not a pharmacokinetic account of exposure in glioma tissue.

    Second, target prediction and pathway enrichment are inherently dependent on reference databases and analytical choices. Shared targets may reflect biological relevance, but they can also reflect incomplete annotations or the prominence of highly connected signaling proteins. Changes in pathway-associated protein expression likewise do not prove direct target engagement or pathway dependence.

    Third, U87, T98G, and GL261 models capture only selected aspects of glioma heterogeneity. A transplanted mouse tumor does not reproduce the full architecture of human infiltrative glioma, including the blood-brain barrier, patient-specific genomic variation, immune context, and interactions with normal neural and vascular cells. The study also does not establish long-term safety, clinical dosing feasibility, or benefit in patients.

    Finally, the paper should not be used to infer that SFI is an angiogenesis inhibitor or that its effects are equivalent to those of a VEGF receptor inhibitor. Although angiogenesis and vascular signaling are relevant to tumor biology, the reported study did not directly establish an endothelial mechanism, quantify vascular remodeling as its primary endpoint, or test a selective VEGFR-directed comparator. These boundaries are especially important when connecting the findings to tumor angiogenesis research or broader anti-cancer claims.

    Research Support Resources

    For separate tumor angiogenesis research, researchers can use AAL-993 (SKU C3730) as a research material described in the supplied product dossier. The dossier identifies it as a selective VEGF receptor inhibitor with reported preclinical anti-angiogenic and melanoma tumor growth inhibition findings, but AAL-993 is not evaluated or mentioned as an intervention in the Shenqi Fuzheng glioma paper. Accordingly, it should be treated as a separate research context, not as validation of the SRC/PI3K/AKT findings or evidence of glioma efficacy.